Curis (CRIS) Q1 Miss: EPS -$1.25 vs -$0.40 est, Revenue $0 vs $1.49M est -- 71.5% Undervalued or Value Trap?
Curis Inc. (CRIS) reported a significant Q1 2026 miss, with GAAP diluted EPS of -$1.25 against an estimated -$0.40, and $0 revenue compared to an estimated $1.49 million. The revenue shortfall was due to the prior sale of Erivedge royalties, while the widened net loss was primarily attributed to a non-cash warrant liability revaluation from a January 2026 PIPE financing. Despite this, the company's cash balance improved, and R&D expenses decreased, indicating disciplined cost management, though its business model remains capital-intensive.
MAY 13·Stock Titan▼
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and flags funding needs
Curis (NASDAQ: CRIS) reported a significantly wider net loss of $24.2 million in Q1 2026, up from $10.6 million in Q1 2025, with revenue dropping to zero after the sale of its Erivedge royalty stream. Despite a January 2026 PIPE financing that boosted cash to $15.0 million, the company indicated current funds are insufficient for the next 12 months and that future operations depend on additional financing, including potential Series B warrant exercises. Curis is advancing emavusertib in multiple cancer trials and expects key clinical data readouts by the end of 2026 and early 2027.
NOV 6·Zacks Commentary▲
Curis ( CRIS ) Reports Q3 Loss, Beats Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of +20.97% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
